Biocartis' Idylla ctKRAS Mutation Assay

Biocartis has launched is second liquid biopsy product, the the Idylla ctKRAS Mutation Assay, which it developed in partnership with Merck. The assay is designed for sensitive and rapid KRAS mutation testing and requires 1 ml of blood plasma. It enables qualitative detection of 21 KRAS mutations, with less than one minute of hands-on time and a turnaround time of approximately 130 minutes.